Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P49588
UPID:
SYAC_HUMAN
Alternative names:
Alanyl-tRNA synthetase; Renal carcinoma antigen NY-REN-42
Alternative UPACC:
P49588; A6NF14; B4DR45; Q53GV7; Q96FA0
Background:
Alanine--tRNA ligase, cytoplasmic, also known as Alanyl-tRNA synthetase and Renal carcinoma antigen NY-REN-42, plays a crucial role in protein synthesis. It catalyzes the attachment of alanine to tRNA(Ala), a fundamental process for translating genetic information into functional proteins. This enzyme not only activates alanine but also ensures accuracy through its editing domain, preventing mischarged tRNA(Ala) from disrupting protein synthesis.
Therapeutic significance:
The enzyme's association with diseases such as Charcot-Marie-Tooth disease, axonal, 2N, Developmental and epileptic encephalopathy 29, Leukoencephalopathy, hereditary diffuse, with spheroids 2, and Trichothiodystrophy 8, non-photosensitive, highlights its potential as a target for therapeutic intervention. Understanding the role of Alanine--tRNA ligase, cytoplasmic could open doors to potential therapeutic strategies, offering hope for patients suffering from these debilitating conditions.